SCLX Scilex Holding Company

AI Employees for E-CommerceBeta

Unlock 24/7 fully automated AI staff for your online store. Experience the future of e-commerce operations—no humans required. Limited closed beta access!

Get Early Access →

Subscribe to $SCLX

Scilex Holding Company

Subscribe to $SCLX

$SCLX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

IPO Year: 2021

Exchange: NASDAQ

Recent Analyst Ratings for Scilex Holding Company

Date	Price Target	Rating	Analyst
1/27/2025	$22.00	Buy	D. Boral Capital
10/16/2024	$14.00	Buy	Alliance Global Partners
6/13/2024	$13.00	Buy	Rodman & Renshaw
10/16/2023	$4.00	Buy	B. Riley Securities
10/13/2023	$4.00	Buy	B. Riley Securities
10/9/2023	$12.00	Buy	H.C. Wainwright

See more ratings

Scilex Holding Company Press Releases

Fastest customizable press release news feed in the world

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIP
5/16/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business
5/9/25 4:00:00 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicia
5/1/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days.
4/30/25 1:46:47 PM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject
4/22/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Pericarditis is an inflammation of the pericardium, the sac-like membrane that surrounds and protects the heart. It occurs when the pericardium becomes irritated or infected, leading to swelling and pain. PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint ven
4/16/25 2:12:04 PM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that on April 11, 2025, the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to extend the date by which the Company must consummate an initial business combination from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight times by an additional one month each time (the "Extension"). The Company also announced today that on April 11, 2025, the Company deposit
4/14/25 4:35:00 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces 1-for-35 Reverse Stock Split
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-35, to be effective as of 12:01 a.m. Eastern Time on April 15, 2025. Scilex's common stock will begin trading on a reverse stock split-adjusted basis at the openi
4/11/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, reiterates that it has appealed a lower court decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and will continue to vigorously pursue its infringement action on appeal against Aveva Drug Delivery Systems, Inc. ("Aveva"). In May 2022, Scilex receive
3/26/25 8:24:29 PM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from March 11, 2025 to April 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a bu
3/11/25 6:13:34 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Scilex Holding Company Financials

Live finance-specific insights

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject
4/22/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record
3/10/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag
1/31/25 9:00:00 AM ET
$SCLX
$SRNE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Commercial Physical & Biological Resarch
Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch
More patients treated with ZTlido® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%).Of all study patients reporting a decrease in opioid use, significantly more in the ZTlido® group experienced a 20% or greater reduction in opioid use, compared with those treated with 5% lidocaine patch (21.3% vs. 13.4%; P=0.0008).Patients on ZTlido® had a non-significant change in their baseline opioid use (+3.1%; P=0.146), while those using the 5% patch experienced a significant increase in opioid use from baseline (+42.9%; P<0.001). PALO ALTO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or
1/13/25 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025
PALO ALTO, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of November 7, 2024 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record
12/30/24 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces Today the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali
As previously announced, Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC")) entered into an agreement and plan of merger, dated as of August 30, 2024 (the "Merger Agreement"), related to the proposed business combination (the "Business Combination") of Denali and Semnur, which provides for a pre-transaction equity value of Semnur of $2.5 billion. The closing of the Business Combination is expected to occur by the first quarter of 2025. As previously disclosed, the Board of Directors of Scilex declared a stock dividend consisting of an aggregate of 5,000,000 shares of Series 1 Mandator
11/6/24 12:24:36 PM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex management is determined to enhance its stockholders' value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock.Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex. Such record date may be changed by Scilex's board of directors for any reason at any time prior to the actual payment of such dividend of Scilex preferred stock. No payment date has been set for the payment of such dividend and such payment is conditioned upon the Scilex board of director
10/29/24 6:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Scilex notified NASDAQ on October 28, 2024 that it has set a record date of November 7, 2024 (the "Record Date") for the dividend of Scilex preferred stock to Scilex's stockholders and certain other securityholders of Scilex.Based on independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™), the product candidate held by Semnur Pharmaceuticals, Inc. ("Semnur") is estimated to have peak sales potential projected to be $3.6 billion annually in the 5th year post launch of SP-102.Scilex previously announced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with
10/28/24 6:00:00 AM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (NASDAQ:DECA, the "SPAC"))).Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scile
10/16/24 4:00:00 AM ET
$DECA
$SCLX
Blank Checks
Finance
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to January 31, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to January 31, 2025. PALO ALTO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management p
9/26/24 9:00:00 AM ET
$SCLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Scilex Holding Company

Recent Analyst Ratings for Scilex Holding Company

Scilex Holding Company

Recent Analyst Ratings for Scilex Holding Company

Scilex Holding Company Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

Scilex Holding Company Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

Director Followwill Dorman bought $990 worth of shares (1,000 units at $0.99), increasing direct ownership by 77% to 2,300 units (SEC Form 4)

Director Chun Jay bought $4,750 worth of shares (5,000 units at $0.95), increasing direct ownership by 5% to 112,500 units (SEC Form 4)

Director Wu Yue Alexander bought $18,992 worth of shares (20,000 units at $0.95), increasing direct ownership by 400% to 25,000 units (SEC Form 4)

Director Lemus David bought $1,800 worth of shares (2,000 units at $0.90) (SEC Form 4)

Executive Chairperson Ji Henry bought $9,710 worth of shares (10,000 units at $0.97) (SEC Form 4)

Officer Shah Jaisim bought $29,751 worth of shares (30,000 units at $0.99), increasing direct ownership by 63% to 77,333 units (SEC Form 4)

Chief Financial Officer Ma Stephen Hoi bought $6,499 worth of shares (6,700 units at $0.97), increasing direct ownership by 42% to 22,840 units (SEC Form 4)

Scilex Holding Company SEC Filings

SEC Form DEF 14A filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 10-Q filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form 424B3 filed by Scilex Holding Company

SEC Form EFFECT filed by Scilex Holding Company

SEC Form EFFECT filed by Scilex Holding Company

Scilex Holding Company Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

D. Boral Capital initiated coverage on Scilex Holding with a new price target

Alliance Global Partners initiated coverage on Scilex Holding with a new price target

Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

B. Riley Securities initiated coverage on Scilex Holding with a new price target

B. Riley Securities initiated coverage on Scilex Holding with a new price target

H.C. Wainwright initiated coverage on Scilex Holding with a new price target

Scilex Holding Company Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Sclx Stock Acquisition Jv Llc disposed of 3,250,000 shares, decreasing direct ownership by 6% to 51,039,214 units (SEC Form 4)

Large owner Sclx Stock Acquisition Jv Llc disposed of 779,371 shares, decreasing direct ownership by 1% to 54,289,214 units (SEC Form 4)

Large owner Sclx Stock Acquisition Jv Llc disposed of 5,000,000 shares, decreasing direct ownership by 8% to 55,068,585 units (SEC Form 4)

Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

SEC Form 4 filed by Director Chun Jay

SEC Form 4 filed by Director Followwill Dorman

SEC Form 4 filed by Director Wu Yue Alexander

Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

Director Followwill Dorman bought $990 worth of shares (1,000 units at $0.99), increasing direct ownership by 77% to 2,300 units (SEC Form 4)

Scilex Holding Company Leadership Updates

Live Leadership Updates

Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

Scilex Holding Company Press Releases

Fastest customizable press release news feed in the world

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company Financials

Live finance-specific insights

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025

Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025